How do hospital characteristics and ties relate to the uptake of second-generation biosimilars? A longitudinal analysis of Portuguese NHS hospitals, 2015–2021

References

• Kesselheim AS, Avorn J, Sarpatwari A. The high cost of prescription drugs in the United States: origins and prospects for reform. J Am Med Assoc. 2016;316(8):858–871.
   PubMed Web of Science ®Google Scholar
• Prasad V, Jesús K D, Mailankody S. The high price of anticancer drugs: origins, implications, barriers, solutions. Nat Rev Clin Oncol. 2017;14(6):381.
   PubMed Web of Science ®Google Scholar
• Rome BN, Egilman AC, Kesselheim AS. Trends in Prescription drug launch prices, 2008-2021. JAMA. 2022;327(21):2145–2147.
   PubMed Web of Science ®Google Scholar
• Rintoul A, Colbert A, Garner S, et al. Medicines with one seller and many buyers: strategies to increase the power of the payer. BMJ. 2020;369. 10.1136/bmj.m1705.
   PubMedGoogle Scholar
• Belloni A, Morgan D, Paris V. Pharmaceutical expenditure and policies [Internet]. OECD iLibrary; 2016. (OECD Health Working Papers). Report No.: 87. Available from: 10.1787/5jm0q1f4cdq7-en
   Google Scholar
• Dranitsaris G, Zhu X, Adunlin G, et al. Cost effectiveness vs. affordability in the age of immuno-oncology cancer drugs. Expert Rev Pharmacoecon Outcomes Res. 2018;18(4):351–357.
   PubMed Web of Science ®Google Scholar
• Vokinger KN, Hwang TJ, Grischott T, et al. Prices and clinical benefit of cancer drugs in the USA and Europe: a cost–benefit analysis. Lancet Oncol. 2020;21(5):664–670.
   PubMed Web of Science ®Google Scholar
• Jang M, Simoens S, Kwon T. Budget impact analysis of the introduction of rituximab and trastuzumab intravenous biosimilars to EU-5 markets. BioDrugs. 2021;35(1):89–101.
   PubMed Web of Science ®Google Scholar
• Kanters TA, Stevanovic J, Huys I, et al. Adoption of biosimilar infliximab for rheumatoid arthritis, ankylosing spondylitis, and inflammatory bowel diseases in the EU5: a budget impact analysis using a Delphi panel. Front Pharmacol. 2017;8:322.
   PubMed Web of Science ®Google Scholar
• Vogler S. Can we achieve affordable cancer medicine prices? Developing a pathway for change. Expert Rev Pharmacoecon Outcomes Res. 2021;21(3):321–325.
   PubMed Web of Science ®Google Scholar
• Stiff KM, Cline A, Feldman SR. Tracking the price of existing biologics when drugs enter the market. Expert Rev Pharmacoecon Outcomes Res. 2019;19(4):375–377.
   PubMed Web of Science ®Google Scholar
• Troein P, Newton M, Scott K, et al. The impact of biosimilar competition in Europe - IQVIA report. Brussels; 2021.
   Google Scholar
• European Commission and European Medicine Agency. Biosimilars in the EU: information guide for health professionals. 2019. https://www.ema.europa.eu/en/documents/leaflet/biosimilars-eu-information-guide-healthcare-professionals_en.pdf
   Google Scholar
• Cohen HP, Blauvelt A, Rifkin RM, et al. Switching reference medicines to biosimilars: a systematic literature review of clinical outcomes. Drugs. 2018;78(4):463–478.
   PubMed Web of Science ®Google Scholar
• Luber RP, O’Neill R, Singh S, et al. An observational study of switching infliximab biosimilar: no adverse impact on inflammatory bowel disease control or drug levels with first or second switch. Aliment Pharmacol Ther. 2021;54(5):678–688.
   PubMed Web of Science ®Google Scholar
• Schreiber S, Ben-Horin S, Leszczyszyn J, et al. Randomized controlled trial: subcutaneous vs intravenous infliximab CT-P13 maintenance in inflammatory bowel disease. Gastroenterology. 2021;160(7):2340–2353.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Statement on the scientific rationale supporting interchangeability of biosimilar medicines in the EU [Internet]. Amsterdam; 2022 [cited 2022 October 19]. Available from: https://www.ema.europa.eu/en/documents/public-statement/statement-scientific-rationale-supporting-interchangeability-biosimilar-medicines-eu_en.pdf
   Google Scholar
• Hübel K, Kron F, Lux MP. Biosimilars in oncology: effects on economy and therapeutic innovations. Eur J Cancer. 2020;139:10–19.
   PubMed Web of Science ®Google Scholar
• Moorkens E, Vulto AG, Huys I. An overview of patents on therapeutic monoclonal antibodies in Europe: are they a hurdle to biosimilar market entry? In: MAbs. Taylor & Francis; 2020. p. 1743517.
   Google Scholar
• Moorkens E, Barcina Lacosta T, Vulto AG, et al. Learnings from regional market dynamics of originator and biosimilar infliximab and etanercept in Germany. Pharmaceuticals. 2020;13(10): 324.
   Web of Science ®Google Scholar
• Beck M, Michel B, Rybarczyk-Vigouret MC, et al. Rheumatologists’ perceptions of biosimilar medicines prescription: findings from a French web-based survey. BioDrugs. 2016;30(6):585–592.
   PubMed Web of Science ®Google Scholar
• Sarnola K, Merikoski M, Jyrkkä J, et al. Physicians’ perceptions of the uptake of biosimilars: a systematic review. BMJ Open. 2020;10(5):e034183.
   PubMed Web of Science ®Google Scholar
• Hakim A, Ross JS. Obstacles to the adoption of biosimilars for chronic diseases. J Am Med Assoc. 2017;317(21):2163–2164.
   PubMed Web of Science ®Google Scholar
• Frantzen L, Cohen JD, Tropé S, et al. Patients’ information and perspectives on biosimilars in rheumatology: a French nation-wide survey. Joint Bone Spine. 2019;86(4):491–496.
   PubMed Web of Science ®Google Scholar
• Azevedo A, Bettencourt A, Selores M, et al. Biosimilar agents for psoriasis treatment: the perspective of Portuguese patients. Acta Med Port. 2018;31(9):496–500.
   PubMed Web of Science ®Google Scholar
• Varma M, Almarsdóttir AB, Druedahl LC. “Biosimilar, so it looks alike, but what does it mean?” A qualitative study of Danish patients’ perceptions of biosimilars. Basic Clin Pharmacol Toxicol. 2022;130(5):581–591.
   PubMed Web of Science ®Google Scholar
• Moorkens E, Vulto AG, Huys I, et al. Policies for biosimilar uptake in Europe: an overview. PLoS One. 2017;12(12): e0190147.
   PubMed Web of Science ®Google Scholar
• Vogler S, Schneider P, Zuba M, et al. Policies to encourage the use of biosimilars in European countries and their potential impact on pharmaceutical expenditure. Front Pharmacol. 2021;12:1479.
   Web of Science ®Google Scholar
• Ferrario A, Dedet G, Humbert T, et al. Strategies to achieve fairer prices for generic and biosimilar medicines. Br Med J. 2020;368:l5444.
   PubMedGoogle Scholar
• Jensen TB, Kim SC, Jimenez-Solem E, et al. Shift from Adalimumab originator to biosimilars in Denmark. JAMA Intern Med. 2020;180(6):902–903.
   PubMed Web of Science ®Google Scholar
• Moorkens E, Godman B, Huys I, et al. Market exclusivity and the entry of adalimumab biosimilars in Europe: an overview of pricing and national policy measures. Frontiers in Pharmacology. 2021;11. 10.3389/fphar.2020.591134.
   PubMed Web of Science ®Google Scholar
• Bennett CL, Schoen MW, Hoque S, et al. Improving oncology biosimilar launches in the EU, the USA, and Japan: an updated policy review from the southern network on adverse reactions. Lancet Oncol. 2020;21(12): e575–88.
   PubMed Web of Science ®Google Scholar
• Moorkens E, Vulto AG, Kent J, et al. A look at the history of biosimilar adoption: characteristics of early and late adopters of infliximab and etanercept biosimilars in subregions of England, Scotland and wales-A mixed methods study. BioDrugs. 2021;35(1): 75–87.
   PubMed Web of Science ®Google Scholar
• Moorkens E, Simoens S, Troein P, et al. Different policy measures and practices between Swedish counties influence market dynamics: part 1—biosimilar and originator infliximab in the hospital setting. BioDrugs. 2019;33(3):285–297.
   PubMed Web of Science ®Google Scholar
• Moorkens E, Simoens S, Troein P, et al. Different policy measures and practices between Swedish counties influence market dynamics: part 2—Biosimilar and originator etanercept in the outpatient setting. BioDrugs. 2019;33(3):299–306.
   PubMed Web of Science ®Google Scholar
• van Overbeeke E, De Beleyr B, de Hoon J, et al. Perception of originator biologics and biosimilars: a survey among Belgian rheumatoid arthritis patients and rheumatologists. BioDrugs. 2017;31(5):447–459.
   PubMed Web of Science ®Google Scholar